American Diabetes Association Highlights Novel Agent Retatrutide Which Results in Substantial Weight Reduction in People With Obesity or Type 2 Diabetes During Late Breaking Symposium
June 27, 2023
June 27, 2023
SAN DIEGO, California, June 27 (TNSjou) -- The American Diabetes Association issued the following news release on June 26, 2023:
Today, findings from two phase 2 clinical trials showcase new data for an investigational, once-weekly injectable glucose-dependent insulinotropic polypeptide (GIP)/ glucagon-like peptide 1 (GLP-1) /glucagon (GCG) receptor agonist, retatrutide. One study was conducted in people with obesity and included a substudy in patients who also had non-alcoholic fat . . .
Today, findings from two phase 2 clinical trials showcase new data for an investigational, once-weekly injectable glucose-dependent insulinotropic polypeptide (GIP)/ glucagon-like peptide 1 (GLP-1) /glucagon (GCG) receptor agonist, retatrutide. One study was conducted in people with obesity and included a substudy in patients who also had non-alcoholic fat . . .